Hospital Jerez Puerta Del Sur Grupo Hla S.A.
- Address
- lock Available on a paid plan
Neoplasms – Melanoma Adjuvant Research
The oncology team at Hospital Jerez Puerta Del Sur Grupo Hla S.A. is evaluating a new nivolumab biosimilar for patients who have undergone resection for stage IIB, IIC, or III melanoma and require adjuvant therapy. The goal is to determine whether the biosimilar can provide comparable effectiveness to the established treatment while offering potential benefits in accessibility.
- Comparative effectiveness of the biosimilar versus reference immunotherapy
- Safety and tolerability in the postoperative setting
- Monitoring of disease‑free survival and recurrence rates
With four investigators leading the effort, this work aims to improve clinical outcomes and expand treatment options for melanoma patients across Europe.
Respiratory Tract Diseases – ARDS Study
In the respiratory unit, researchers are testing metoprolol as a novel approach to treat Acute Respiratory Distress Syndrome (ARDS). The trial focuses on increasing the number of days alive and free of invasive mechanical ventilation within the first 28 days, seeking to reduce the burden of prolonged ventilation.
- Evaluation of beta‑blocker impact on lung inflammation
- Reduction of duration of invasive ventilation
- Early safety and hemodynamic monitoring
Conducted by a team of four investigators, the study strives to demonstrate a meaningful clinical benefit for patients facing severe respiratory failure.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1H e x a l AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Jerez Puerta Del Sur Grupo Hla S.A.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Pharmacokinetic Comparison of JPB898 and Nivolumab in Patients with Resected Stage IIB, IIC, or III Melanoma in the Adjuvant Setting | H e x a l AG | Phase I | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apalutamide | 1 | Unknown | 2019-07-11 | 2019-07-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.